Table 1.
Demographic Characteristics of the Exposed and Unexposed Study Participants
| SARS-Cov-2 Unexposed Patients | ||||||||
|---|---|---|---|---|---|---|---|---|
| Number | Age, y (Transplant Cohort) | Women (%), Transplant Cohort (%) | Sample Collection Dates | Transplant (%) | Characterization of T Cells (Number of Transplant Participants) | Characterization of B Cells (Number of Participants) | ||
| 26 | N/A | 11 (42%)-5 (36%) | 2017-2020 | 14 (54%) | 18 (7) | 26 | ||
| Median | N/A | 69 (55) | N/A | N/A | N/A | N/A | N/A | |
| Minimum | N/A | 37 (37) | N/A | N/A | N/A | N/A | N/A | |
| Maximum | N/A | 91 (75) | N/A | N/A | N/A | N/A | N/A | |
| Convalescent COVID-19 Patients | ||||||||
|---|---|---|---|---|---|---|---|---|
| Age, y | Sex | SARS-CoV-2 PCR | Sample Collection Day (Day 1 = 1st Positive PCR) | Disease Severity | Disease Outcome | Characterization of T Cells | Characterization of B cells | |
| CoV1 | 64 | W | positive | 110 | severe | Recovery | x | x |
| CoV2 | 65 | W | positive | 121 | mild | Recovery | x | |
| CoV3 | 60 | M | positive | 121 | mild | Recovery | x | |
| CoV4 | 60 | M | positive | 121 | mild | Recovery | x | |
| CoV5 | 73 | M | positive | 79 | severe | Recovery | x | |
| CoV6 | 45 | W | positive | 45 | moderate | Recovery | x | |
| CoV7 | 67 | M | positive | 62 | severe | Recovery | x | |
| CoV8 | 89 | W | positive | 36 | severe | Recovery | x | |
| CoV9 | 52 | W | positive | 178 | mild | Recovery | x | |
| CoV10 | 75 | M | positive | 178 | mild | Recovery | x | |
| CoV11 | 83 | W | positive | 22 | severe | Recovery | x | |
| CoV12 | 28 | W | positive | 198 | mild | Recovery | x | |
| CoV13 | 61 | W | positive | 147 | mild | Recovery | x | |
| CoV14 | 55 | M | positive | 100 | unknown | Recovery | x | |
| CoV15 | 63 | M | positive | 113 | asymptomatic | Recovery | x | |
| CoV16 | 75 | M | positive | 133 | severe | Recovery | x | |
| CoV17 | 45 | M | positive | 32 | critical | Recovery | x | |
| CoV18 | 88 | W | positive | 34 | severe | Recovery | x | |
| CoV19 | 53 | M | positive | 30 | critical | Recovery | x | |
| CoV20 | 52 | W | positive | 23 | asymptomatic | Recovery | x | |
| CoV21 | 56 | W | positive | 120 | asymptomatic | Recovery | x | |
| CoV22 | 47 | W | positive | 103 | asymptomatic | Recovery | x | |
| No. (%) | NA | 12 (55%) | N/A | N/A | N/A | N/A | 9 | 14 |
| Median | 54,5 | N/A | N/A | 110 | N/A | N/A | N/A | N/A |
| Minimum | 28 | N/A | N/A | 22 | N/A | N/A | N/A | N/A |
| Maximum | 89 | N/A | N/A | 198 | N/A | N/A | N/A | N/A |
M, man; PCR, polymerase chain reaction; W, woman.